منابع مشابه
Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
B reast cancer is the most commonly diagnosed cancer in women and the second-leading cause of death among women with cancer. Whereas outcomes for many breast cancers are favorable, human epidermal growth factor receptor-2 (HER2)-positive breast cancers may have an aggressive clinical course and are associated with higher rates of disease recurrence and mortality. Such tumors are characterized b...
متن کاملResistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملTargeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
About 20% of all breast cancer patients have a human epidermal growth factor receptor 2 (HER2)-positive breast tumor. This entity underwent an impressive change in prognosis, with notable improvement of progression-free survival and overall survival. Due to more aggressive tumors and no specific therapy, HER2 overexpression was historically seen as a negative prognostic marker, with worse progn...
متن کاملTargeted therapies for ER+/HER2- metastatic breast cancer
The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal growth factor receptor (HER2)-negative features and might benefit from endocrine therapy. Although endocrine therapy has notably evolved during the last decades, the invariable appearance of endocrine resistance, either primary or secondary, remains an important issue in this type of tumor. The impro...
متن کاملThe role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the improvement in outcomes with the adjuvant use of trastuzumab in patients with early-stage breast cancer positive for the human epidermal growth fact...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in Cardiology
سال: 2019
ISSN: 0268-4705
DOI: 10.1097/hco.0000000000000637